RT Journal Article
SR Electronic
T1 Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.07.24311621
DO 10.1101/2024.08.07.24311621
A1 Liu, Yaozhong
A1 Wang, Huilun
A1 Yu, Minzhi
A1 Cai, Lei
A1 Zhao, Ying
A1 Cheng, Yalun
A1 Deng, Yongjie
A1 Zhao, Yang
A1 Lu, Haocheng
A1 Wu, Xiaokang
A1 Zhao, Guizhen
A1 Xue, Chao
A1 Liu, Hongyu
A1 Surakka, Ida
A1 Schwendeman, Anna
A1 Lu, Hong S.
A1 Daugherty, Alan
A1 Chang, Lin
A1 Zhang, Jifeng
A1 Temel, Ryan E.
A1 Chen, Y. Eugene
A1 Guo, Yanhong
YR 2024
UL http://medrxiv.org/content/early/2024/08/12/2024.08.07.24311621.abstract
AB Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medications. This study integrated genetic, proteomic, and metabolomic data to identify causation between increased triglyceride (TG)-rich lipoproteins and AAA risk. Three hypertriglyceridemia mouse models were employed to test the hypothesis that increased plasma TG concentrations accelerate AAA development and rupture. In the angiotensin II-infusion AAA model, most Lpl-deficient mice with severely high plasma TG concentrations died of aortic rupture. Consistently, Apoa5-deficient mice with moderately increased TG concentrations had accelerated AAA development, while human APOC3 transgenic mice with dramatically increased TG concentrations exhibited aortic dissection and rupture. Increased TG concentrations and palmitate inhibited lysyl oxidase maturation. Administration of antisense oligonucleotide targeting Angptl3 profoundly inhibited AAA progression in human APOC3 transgenic mice and Apoe-deficient mice. These results indicate that hypertriglyceridemia is a key contributor to AAA pathogenesis, highlighting the importance of triglyceride-rich lipoprotein management in treating AAA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially supported by the National Institutes of Health grants HL166203 (Y.G.), HL165688 (Y.G. and A.S.), HL109946 and HL134569 (Y.E.C.), HL151524 (L.C.), HL153710 and HL138139 (J.Z.), HL172832 (G. Zhao), R35HL155649 (A.D.), UL1TR001998 (A.D.), R21 NS11191 (A.S.) and the American Heart Association Merit award 23MERIT1036341 (A.D.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All genetic data used in this study were obtained from publicly available consortiums.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes